In the latest edition of The Cancer Letter, NBCC’s Chief Programs Officer Michelle Tregear expanded upon NBCC’s recent statement on the Food and Drug Administration (FDA) hormone replacement therapy (HRT) black box warning removal:
We would probably agree that the black box warning was not appropriate for current day uses of the new formulations, but you don’t just simply remove those black box warnings… We need to follow the robust, evidence-based processes in making these decisions, in part to ensure that people have trust in the decisions that are being made.
